首页> 外文期刊>European review for medical and pharmacological sciences. >Increased expression of miR-1179 inhibits breast cancer cell metastasis by modulating Notch signaling pathway and correlates with favorable prognosis
【24h】

Increased expression of miR-1179 inhibits breast cancer cell metastasis by modulating Notch signaling pathway and correlates with favorable prognosis

机译:miR-1179表达增加可通过调节Notch信号通路抑制乳腺癌细胞转移,并与预后相关

获取原文
           

摘要

OBJECTIVE: MicroRNAs (miRNAs) play a key role in the regulation of gene expression. In this study, we aimed to identify the clinical values of miR-1179 and to investigate the potential molecular mechanisms in breast cancer (BC). MATERIALS AND METHODS: RT-PCR was used to detect the expression levels of miR-1179 in both BC tissues and cell lines. We analyzed the association between the miR-1179 levels and clinicopathological factors and patient prognosis. The proliferation ability of miR-1179 on BC cells was assessed by MTT and colony formation assay. The role of miR-1179 in BC cells migration and invasion was measured by transwell assays. Western blot analysis was used to quantify the expression of the molecular biomarkers of the Notch signaling pathway. RESULTS: Our results showed that miR-1179 expression was frequently downregulated in BC tissues and cell lines. Clinicopathologic analysis revealed that low miR-1179 expression is correlated with lymph node metastasis, advanced clinical stage and shorter overall survival. Multivariable Cox proportional hazards regression analysis suggested that increased miR-1179 expression was an independent prognostic factor of overall survival in BC patients. Gain-of-function assay indicated that the overexpression of miR-1179 significantly suppressed BC cells proliferation, migration and invasion. Mechanistically, miR-1179 up-regulation inhibited the expression of Notch 1, Notch 4 and Hes1, indicating that miR-1179 could suppress the activation of the Notch signaling pathway. CONCLUSIONS: We showed that miR-1179 was a tumor suppressor that may serve as a novel potential prognostic biomarker or molecular therapeutic target for BC.
机译:目的:微小RNA(miRNA)在调节基因表达中起关键作用。在这项研究中,我们旨在确定miR-1179的临床价值,并研究乳腺癌(BC)的潜在分子机制。材料与方法:采用RT-PCR检测miR-1179在BC组织和细胞系中的表达水平。我们分析了miR-1179水平与临床病理因素与患者预后之间的关联。通过MTT和集落形成试验评估miR-1179在BC细胞上的增殖能力。 miR-1179在BC细胞迁移和侵袭中的作用通过transwell测定法进行了测量。 Western印迹分析用于量化Notch信号通路分子生物标志物的表达。结果:我们的结果表明,miR-1179表达在BC组织和细胞系中经常被下调。临床病理分析表明,miR-1179的低表达与淋巴结转移,晚期临床分期和较短的总生存期有关。多变量Cox比例风险回归分析表明,miR-1179表达增加是BC患者总体生存的独立预后因素。功能增益分析表明,miR-1179的过表达显着抑制了BC细胞的增殖,迁移和侵袭。从机制上讲,miR-1179的上调抑制了Notch 1,Notch 4和Hes1的表达,表明miR-1179可以抑制Notch信号通路的激活。结论:我们表明miR-1179是一种肿瘤抑制因子,可作为BC的新型潜在预后生物标志物或分子治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号